Mibrex

Rivaroxaban, the active ingredient in Mibrex, is a direct factor Xa inhibitor presented as an oral tablet for oral use. It is indicated for the prevention of stroke and systemic embolism in non‑valvular atrial fibrillation, and for the treatment and secondary prevention of deep vein thrombosis and pulmonary embolism.

GNH USA supplies Mibrex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export, ensuring product integrity.

Mibrex (rivaroxaban) acts on the coagulation cascade to reduce thrombus formation in several venous and arterial conditions.

- Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism. - Deep vein thrombosis (DVT): treats acute DVT and prevents clot extension. - Pulmonary embolism (PE): treats acute PE and lowers recurrence risk. - Venous thromboembolism prophylaxis after orthopedic surgery: prevents postoperative clot formation.

Mibrex may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Minor bleeding such as gum or nosebleeds. - Easy bruising. - Nausea. - Diarrhea.

Serious or Rare Side Effects: - Intracranial hemorrhage. - Gastrointestinal bleeding. - Spinal or epidural hematoma. - Severe allergic reaction (anaphylaxis).

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients closely. - Renal function assessment: adjust use in impaired kidney function. - Hepatic impairment caution: avoid in severe liver disease. - Concomitant anticoagulant use: increase bleeding risk. - Surgical or invasive procedures: discontinue as advised to reduce peri‑procedural bleeding. - Pregnancy and breastfeeding: safety not established; generally avoided. - Store at room temperature: keep in the original container, protect from moisture and light.

Rivaroxaban interacts with several drug classes that can alter its anticoagulant effect.

Major Interactions (Avoid): - Combined use with other anticoagulants (e.g., warfarin, heparin). - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir).

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin). - Antiplatelet agents (e.g., clopidogrel) when bleeding risk is high. - NSAIDs (e.g., ibuprofen) in patients prone to bleeding.